PL2352508T3 - Peptydy domeny cytoplazmatycznej MUC-1 jako inhibitory nowotworu - Google Patents

Peptydy domeny cytoplazmatycznej MUC-1 jako inhibitory nowotworu

Info

Publication number
PL2352508T3
PL2352508T3 PL09740811T PL09740811T PL2352508T3 PL 2352508 T3 PL2352508 T3 PL 2352508T3 PL 09740811 T PL09740811 T PL 09740811T PL 09740811 T PL09740811 T PL 09740811T PL 2352508 T3 PL2352508 T3 PL 2352508T3
Authority
PL
Poland
Prior art keywords
muc
inhibitors
cancer
cytoplasmic domain
domain peptides
Prior art date
Application number
PL09740811T
Other languages
English (en)
Inventor
Donald W Kufe
Surender Kharbanda
Original Assignee
Dana Farber Cancer Inst Inc
Genus Oncology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Genus Oncology Llc filed Critical Dana Farber Cancer Inst Inc
Publication of PL2352508T3 publication Critical patent/PL2352508T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL09740811T 2008-10-17 2009-10-16 Peptydy domeny cytoplazmatycznej MUC-1 jako inhibitory nowotworu PL2352508T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10638008P 2008-10-17 2008-10-17
US17710909P 2009-05-11 2009-05-11
PCT/US2009/061051 WO2010045586A2 (en) 2008-10-17 2009-10-16 Muc-1 cytoplasmic domain peptides as inhibitors of cancer
EP09740811.6A EP2352508B1 (en) 2008-10-17 2009-10-16 Muc-1 cytoplasmic domain peptides as inhibitors of cancer

Publications (1)

Publication Number Publication Date
PL2352508T3 true PL2352508T3 (pl) 2014-09-30

Family

ID=42046194

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09740811T PL2352508T3 (pl) 2008-10-17 2009-10-16 Peptydy domeny cytoplazmatycznej MUC-1 jako inhibitory nowotworu

Country Status (19)

Country Link
US (3) US8524669B2 (pl)
EP (2) EP2352508B1 (pl)
JP (2) JP5657549B2 (pl)
KR (1) KR101689408B1 (pl)
CN (1) CN102245632B (pl)
AU (1) AU2009305550B2 (pl)
BR (1) BRPI0920360A2 (pl)
CA (1) CA2741065C (pl)
DE (1) DE09740811T9 (pl)
DK (1) DK2352508T3 (pl)
ES (1) ES2395028T3 (pl)
IL (1) IL212383A (pl)
MX (1) MX2011004082A (pl)
NZ (1) NZ592537A (pl)
PL (1) PL2352508T3 (pl)
PT (1) PT2352508E (pl)
RU (1) RU2539832C2 (pl)
WO (1) WO2010045586A2 (pl)
ZA (1) ZA201103150B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5657549B2 (ja) 2008-10-17 2015-01-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の阻害剤としてのｍｕｃ−１細胞質ドメインペプチド
JP5702371B2 (ja) 2009-05-27 2015-04-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害
US8685928B2 (en) * 2010-02-12 2014-04-01 Dana-Farber Cancer Institute, Inc. Antagonists of MUC1
WO2011115819A2 (en) * 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
KR20130115108A (ko) 2010-05-28 2013-10-21 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 올리고－벤즈아미드 화합물 및 이의 용도
US8907054B2 (en) * 2011-08-08 2014-12-09 Marquette University Dpy-30 binding peptides
KR102049928B1 (ko) * 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도
US10258676B2 (en) * 2011-09-06 2019-04-16 Agency For Science, Technology And Research Polypeptide vaccine
WO2013078277A1 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
WO2013078288A1 (en) * 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Oligo-benzamide compounds for use in treating cancers
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
US9572855B2 (en) 2013-03-11 2017-02-21 Dana-Farber Cancer Institute, Inc. Combination anti-estrogen receptor cancer therapy using MUC1 peptides and chemotherapeutics
US9789156B2 (en) * 2013-03-11 2017-10-17 Dana-Farber Cancer Institute, Inc. Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
ES2794088T3 (es) 2014-01-29 2020-11-17 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de MUC1-C (MUC1-C/ECD)
CA2888068A1 (en) 2014-04-15 2015-10-15 The Hospital For Sick Children Cationic antimicrobial peptides
EP3542814B1 (en) 2018-03-21 2022-08-24 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Novel peptide-based compounds for use in the prevention, treatment and/or detection of cancer
WO2025217515A2 (en) 2024-04-12 2025-10-16 Dana-Farber Cancer Institute, Inc. Identification of muc1-c as a target for the treatment of squamous cell carcinomas
CN119236051B (zh) * 2024-09-29 2025-12-19 北京大学 Muc1抑制剂在制备预防、治疗细菌感染药物中的应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
NZ255256A (en) 1992-08-27 1997-02-24 Deakin Res Ltd Synthetic peptide antigen analogues with retro, inverso or retro-inverso modification, their use and antibodies against them
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5912232A (en) 1994-09-23 1999-06-15 Board Of Regents Of The University Of Nebraska Anti-inflammatory polypeptide antagonists of human I1-8
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US5597457A (en) 1995-01-23 1997-01-28 The Regents Of The University Of California System and method for forming synthetic protein crystals to determine the conformational structure by crystallography
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
NO961031D0 (no) * 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US20020044943A1 (en) 1997-09-10 2002-04-18 Longenecker B. Michael MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
EP1105523A4 (en) 1998-08-13 2002-09-25 Wyeth Corp ESCHERICHIA COLI GDP-FUCOSE SYNTHETASE CRYSTALLINE STRUCTURE AND METHODS OF USE THEREOF
AU4218799A (en) 1998-08-25 2000-03-14 Scripps Research Institute, The Methods and systems for predicting protein function
US20010047183A1 (en) 2000-04-05 2001-11-29 Salvatore Privitera Surgical device for the collection of soft tissue
WO2000034468A2 (en) 1998-12-11 2000-06-15 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US6801860B1 (en) 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AU5298900A (en) 1999-05-26 2000-12-12 Regents Of The University Of California, The Method of determining the three-dimensional shape of a macromolecule
JP2003507438A (ja) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
DE60030450T2 (de) 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
WO2001057068A1 (en) * 2000-02-01 2001-08-09 The Austin Research Institute Mucin-1 derived antigens and their use in immunotherapy
CN1455680A (zh) 2000-09-11 2003-11-12 达纳-法伯癌症协会有限公司 Muc1胞外域和癌症治疗组合物及方法
WO2002022154A2 (en) 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
AU2002246791C1 (en) * 2000-12-22 2008-04-03 Dana-Farber Cancer Institute, Inc. Regulation of cell growth by MUC1
US7118862B2 (en) 2001-04-18 2006-10-10 Dana-Farber Cancer Institute, Inc. Induction of apoptosis by cellular stress
WO2003017032A2 (en) 2001-08-14 2003-02-27 Dana-Farber Cancer Institute, Inc. Computer-based methods of designing molecules
US7247297B2 (en) 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
CA2842429A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
JP2004137207A (ja) * 2002-10-18 2004-05-13 Keio Gijuku 細胞毒性を抑制する蛋白質
WO2004043141A2 (en) * 2002-11-07 2004-05-27 Agritech Technology, Ltd Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians
EP1587908A4 (en) * 2003-01-09 2008-02-20 Invitrogen Corp RELEASE AND ACTIVATION OF COMPLEX CELLS OF POLYPEPTIDES AND NUCLEIC ACIDS
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
EP1538164A1 (en) 2003-12-04 2005-06-08 Vectron Therapeutics AG RGD targeting moiety its production and use
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
EP1720910A4 (en) * 2004-02-17 2007-11-21 Cancervax Corp METHOD AND COMPOSITION FOR INHIBITING ANGIOGENESIS
EP1718367A1 (en) 2004-02-23 2006-11-08 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
DK1725580T3 (da) * 2004-03-17 2009-03-23 Aplagen Gmbh Isosterisk transformation
WO2005101021A1 (en) 2004-04-13 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled adrenergic alpha-1d-receptor (adra1d)
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
CA2597627A1 (en) 2005-02-15 2006-08-24 Dana-Farber Cancer Institute, Inc. Modulation of muc1 activity
CA2601823C (en) 2005-04-15 2016-01-12 University Of Arizona Therapeutic peptides for the treatment of metastatic cancer
CA2614307A1 (en) * 2005-05-26 2006-11-30 Dana-Farber Cancer Institute, Inc. Modulation of muc1-dependent anti-estrogen resistance
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007024940A2 (en) 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
CN101448938A (zh) * 2006-03-28 2009-06-03 佐藤升志 新肿瘤抗原肽
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US8012695B2 (en) 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
JP5657549B2 (ja) 2008-10-17 2015-01-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の阻害剤としてのｍｕｃ−１細胞質ドメインペプチド
JP5702371B2 (ja) 2009-05-27 2015-04-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害
US8685928B2 (en) 2010-02-12 2014-04-01 Dana-Farber Cancer Institute, Inc. Antagonists of MUC1
WO2011115819A2 (en) 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same

Also Published As

Publication number Publication date
US20120172312A1 (en) 2012-07-05
DK2352508T3 (da) 2014-04-28
EP2352508B1 (en) 2014-04-02
CN102245632A (zh) 2011-11-16
KR101689408B1 (ko) 2016-12-23
HK1160795A1 (en) 2012-08-17
MX2011004082A (es) 2011-10-14
US20100125055A1 (en) 2010-05-20
AU2009305550A1 (en) 2010-04-22
CN102245632B (zh) 2018-10-12
EP2352508A2 (en) 2011-08-10
JP5657549B2 (ja) 2015-01-21
IL212383A0 (en) 2011-06-30
ES2395028T3 (es) 2014-05-30
CA2741065C (en) 2017-04-25
WO2010045586A8 (en) 2011-08-04
US20150152152A1 (en) 2015-06-04
US8524669B2 (en) 2013-09-03
JP2015096513A (ja) 2015-05-21
KR20110093801A (ko) 2011-08-18
US9546201B2 (en) 2017-01-17
EP2727601B1 (en) 2018-06-13
WO2010045586A2 (en) 2010-04-22
AU2009305550B2 (en) 2014-06-12
US8957185B2 (en) 2015-02-17
RU2011119606A (ru) 2012-11-27
EP2727601A1 (en) 2014-05-07
ZA201103150B (en) 2014-12-23
JP2012505922A (ja) 2012-03-08
CA2741065A1 (en) 2010-04-22
RU2539832C2 (ru) 2015-01-27
DE09740811T9 (de) 2013-10-31
ES2395028T1 (es) 2013-02-07
IL212383A (en) 2017-10-31
WO2010045586A3 (en) 2011-01-13
DE09740811T1 (de) 2012-03-22
BRPI0920360A2 (pt) 2021-03-02
NZ592537A (en) 2012-07-27
JP6030622B2 (ja) 2016-11-24
PT2352508E (pt) 2014-05-26

Similar Documents

Publication Publication Date Title
IL212383A0 (en) Muc-1 cytoplasmic domain peptides as inhibitors of cancer
GB2471987B (en) Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) Anti-tumoural effects of cannabinoid combinations
EP2297174A4 (en) EXCLUSIVE SYNTHESIS OF GALACTOSIDE INHIBITORS
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL208719A0 (en) Inhibitors of protein kinases
EP2318395A4 (en) IPA INHIBITORS
EP2364487A4 (en) PROVIDING PLACE-BASED ADVERTISING
PL2373157T3 (pl) Dyspersje zawierające inhibitory dioksygenazy hydroksyfenylopirogronianowej
ZA201100898B (en) Novel inhibitors
GB0820970D0 (en) Suppression of cancer
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
GB0820309D0 (en) Detection of cancer
ZA201004765B (en) Inhibitors of iap
GB0811091D0 (en) CYP26 Inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
PL2306995T3 (pl) Właściwości przeciwnowotworowe inhibitorów proteazy zmodyfikowanych NO
PL2411376T3 (pl) Inhibitory nf-kb
GB0808286D0 (en) Inhibitors of HSP90
GB201019387D0 (en) Inhibitors
GB0816125D0 (en) Novel inhibitors
HK1160453A (en) Phosphodiestarase inhibitors
GB0803895D0 (en) Inhibitors of glyoxalase